Autolus Therapeutics plc(AUTL)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,574 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
AUTL Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Autolus Therapeutics plc (AUTL), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores AUTL at 27.8/100 on a 32-signal composite quality model, placing it at rank #2,574 of 2,962 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), Autolus Therapeutics plc reports quarterly revenue of $45.7M, net income of $-39.1M, free cash flow of $-26.0M. Top institutional holders of AUTL by reported 13-F value include MAK CAPITAL ONE, Blackstone, Syncona Portfolio Ltd, based on the most recent SEC filings. AUTL trades on the Nasdaq exchange and files with the SEC under CIK 1730463. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AUTL daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Autolus Therapeutics plc directly from SEC EDGAR. Autolus Therapeutics plc's 13F Pro composite quality score has ranged between 10 and 29 since 2026, currently 27.8 — a stable long-term trajectory across 48 quarterly and live scoring snapshots.
Revenue
Q2 2026
$45.7M
Net Income
Q2 2026
$-39.1M
Free Cash Flow
Q2 2026
$-26.0M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+644.9% YoYNet Income
-30.3% YoYOperating Income
-12.1% YoYEPS (Diluted)
-25.6% YoYTotal Assets
-24.7% YoYOp. Cash Flow
-37.5% YoYFree Cash Flow
-32.5% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $75.4M +644.9% | $10.1M +496.0% | $1.7M | — | — | — |
| Net Income | $-287.5M -30.3% | $-220.7M -5.9% | $-208.4M -40.0% | $-148.8M -4.7% | $-142.1M -0.0% | $-142.1M |
| Operating Income | $-270.5M -12.1% | $-241.4M -34.3% | $-179.7M -25.3% | $-143.4M -1.7% | $-141.1M +16.1% | $-168.1M |
| EPS (Diluted) | $-1.08 -25.6% | $-0.86 +28.3% | $-1.20 +23.6% | $-1.57 +20.3% | $-1.97 +28.6% | $-2.76 |
| Total Assets | $589.1M -24.7% | $782.7M +108.5% | $375.4M -23.4% | $490.3M +20.9% | $405.6M +37.8% | $294.2M |
| Operating Cash Flow | $-283.6M -37.5% | $-206.3M -41.7% | $-145.6M -29.6% | $-112.3M +4.7% | $-117.9M -0.1% | $-117.8M |
| Free Cash Flow | $-302.6M -32.5% | $-228.3M -45.8% | $-156.6M -27.1% | $-123.1M +2.8% | $-126.7M +4.3% | $-132.4M |
Get alerted when AUTL's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Autolus Therapeutics plc including:
Top Institutional Holders of AUTL
MAK CAPITAL ONE LLC
$53.8M33,621,487 shBlackstone Inc.
$32.8M20,485,611 shSyncona Portfolio Ltd
$26.6M16,640,720 shARMISTICE CAPITAL, LLC
$24.0M15,000,000 shTFG Asset Management GP Ltd
$15.2M9,500,000 shSCHRODER INVESTMENT MANAGEMENT GROUP
$12.9M7,833,282 shFrazier Life Sciences Management, L.P.
$7.1M4,447,910 shBNP Paribas Asset Management Holding S.A.
$5.4M3,361,156 shLaurion Capital Management LP
$5.3M3,316,626 shRENAISSANCE TECHNOLOGIES LLC
$3.2M1,984,700 sh
| Fund | Value | Shares |
|---|---|---|
| MAK CAPITAL ONE LLC | $53.8M | 33,621,487 |
| Blackstone Inc. | $32.8M | 20,485,611 |
| Syncona Portfolio Ltd | $26.6M | 16,640,720 |
| ARMISTICE CAPITAL, LLC | $24.0M | 15,000,000 |
| TFG Asset Management GP Ltd | $15.2M | 9,500,000 |
| SCHRODER INVESTMENT MANAGEMENT GROUP | $12.9M | 7,833,282 |
| Frazier Life Sciences Management, L.P. | $7.1M | 4,447,910 |
| BNP Paribas Asset Management Holding S.A. | $5.4M | 3,361,156 |
| Laurion Capital Management LP | $5.3M | 3,316,626 |
| RENAISSANCE TECHNOLOGIES LLC | $3.2M | 1,984,700 |
Companies Similar to AUTL
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
AGIOS PHARMACEUTICALS, INC.
BICYCLE THERAPEUTICS PLC
Syndax Pharmaceuticals Inc
CYTOKINETICS INC
Foghorn Therapeutics Inc.
ARS Pharmaceuticals, Inc.
Kymera Therapeutics, Inc.
UroGen Pharma Ltd.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put AUTL on your watchlist
Track score changes the day Autolus Therapeutics plc files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is AUTL a good stock to buy?
13F Pro's AI-powered analysis of Autolus Therapeutics plc (AUTL) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for AUTL are available on the AUTL stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. AUTL is classified as a small company.
Which hedge funds own AUTL?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling AUTL. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Autolus Therapeutics plc's investment landscape.